Rigel Pharmaceuticals' SWOT analysis: stock poised for growth …

Dec 13, 2024 · TAVALISSE's slower-than-expected growth poses a significant challenge for Rigel Pharmaceuticals. As one of the company's key products, its performance directly impacts overall revenue and ...

$57
OFF

Rigel Pharmaceuticals Reports Preliminary Q4 Results; Issues

1 week from now

3 days ago · (RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. …

nasdaq.com

$458
OFF

Is Rigel Pharmaceuticals, Inc. (RIGL) Stock A Good Investment?

1 week from now

Nov 14, 2024 · Latest Rigel Pharmaceuticals, Inc. Stock News. As of December 05, 2024, Rigel Pharmaceuticals, Inc. had a $458.5 million market capitalization, putting it in the 39th …

aaii.com

$17
OFF

Rigel Pharmaceuticals Stock Hits 52-week High At $17.5

1 week from now

Nov 8, 2024 · Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) stock soared to a 52-week high, reaching a price level of $17.5, marking a significant milestone for the company.This peak …

investing.com

$7.45
OFF

Madrigal Pharmaceuticals' SWOT Analysis: Stock Poised For Growth …

1 week from now

Jan 10, 2025 · Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company with a market capitalization of $7.45 billion focused on developing treatments for …

investing.com

100%
OFF

Eli Lilly's SWOT Analysis: Stock Poised For Growth Despite Challenges

1 week from now

2 days ago · 狼 Unfair Advantage: 10 bargain stocks found using this simple tool See undervalued stocks Get 100% ad-free experience Eli Lilly's SWOT analysis: stock poised for growth despite …

investing.com

FAQs about Rigel Pharmaceuticals' SWOT analysis: stock poised for growth … Coupon?

Should you buy Rigel Pharmaceuticals (Rigl)?

Rigel Pharmaceuticals is a commercial-stage biotechnology company developing innovative treatments for hematologic disorders and cancer. Since my initial article in July, in which I rated RIGL a “Strong Buy,” the stock has rallied by about 50.1%. Yet, I believe RIGL still looks like a compelling investment. ...

Who owns Rigel Pharmaceuticals (Rigel) stock?

In the past three months, Rigel Pharmaceuticals insiders have not sold or bought any company stock. Only 9.04% of the stock of Rigel Pharmaceuticals is held by insiders. 66.23% of the stock of Rigel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. ...

Why has Rigel Pharmaceuticals soared 50 percent?

Rigel Pharmaceuticals has surged 50.1% since my previous article, driven by successful execution, innovative portfolio, strategic partnerships, and pipeline progress. RIGL's FDA-approved drugs, Tavalisse, Rezlidhia, and Gavreto, are key revenue drivers. ...

What was Rigel Pharmaceuticals' stock price in 2024?

Rigel Pharmaceuticals' stock was trading at $14.50 at the beginning of 2024. Since then, RIGL stock has increased by 13.8% and is now trading at $16.50. How were Rigel Pharmaceuticals' earnings last quarter? Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings results on Tuesday, August, 6th. ...

What does Rigel Pharmaceuticals do?

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. ...

Does Rigel Pharmaceuticals pay a dividend?

Rigel Pharmaceuticals does not currently pay a dividend. Rigel Pharmaceuticals does not have a long track record of dividend growth. Rigel Pharmaceuticals has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). ...